Tests
PrevIOTOX
PrevIOTOX testing
While immunotherapy has been a breakthrough in cancer treatment, patients often experience a new type of side effect, referred to as Immune-Related Adverse Events (irAEs). We have found that the germline genetic mutations we study at MiraDX can help predict a patient’s risk of irAEs from immune therapy.
Our first panel, PrevIOTOX, predicts up to a 9 fold increased risk of irAEs from treatment with anti-PD1 or anti-PDL1 therapies.
Would you like to join our clinics in piloting the PrevIOTOX program?
Please contact us.
PrevIOTOX Testing Populations
Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing.
This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment.
Begin PrevIOTOX Testing
Would you like to join our clinics in using the PROSTOX program? Please contact us here to arrange a webinar or in-person visit.